Notice of Full Year Results ended May 2019

RNS Number : 0783R

Oncimmune Holdings PLC

25 October 2019

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Full Year Results ended May 2019

25 October 2019 - Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, will be announcing its full year results for the year ended 31 May 2019 on Thursday 31 October 2019.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call  for analysts at 10:00am GMT on the day of the results at the office of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD.

For conference call details please contact Alexander Davis at FTI Consulting at [e-mail] or 020 3727 1000.

For further information:

Oncimmune Holdings plc

Matthew Hall, Chief Financial Officer

[e-mail]

Cléa Rosenfeld, Head of Investor Relations

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

[phone]

finnCap Limited (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

[phone]

Media enquiries:

FTI Consulting

Brett Pollard, Andrew Ward

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com

 

END

 

 

NORCKQDBPBDDDKB